TITLE

Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?

AUTHOR(S)
Besada, Emilio; Nossent, Johannes
PUB. DATE
November 2013
SOURCE
Clinical Rheumatology;Nov2013, Vol. 32 Issue 11, p1677
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports in haematology, transplantation medicine and rheumatology indicate that Rituximab, a B cell depleting therapy, increases the risk for Pneumocystis jiroveci pneumopathy. Patients with antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis have an increased incidence of P. jiroveci pneumopathy compared to other autoimmune diseases and Rituximab is often used to induce and maintain remission. Herein, we present a case of a patient with granulomatosis with polyangiitis treated with Rituximab for relapse that developed P. jiroveci pneumopathy 3 months after and we review the relevant literature to assess P. jiroveci pneumopathy incidence and risks factors under Rituximab. We also discuss whether P. jiroveci screening before Rituximab and P. jiroveci pneumopathy prophylaxis under Rituximab are indicated. P. jiroveci colonisation is found in 25 % of patients with autoimmune diseases. However, the association between colonisation and P. jiroveci pneumopathy development is not very strong. P. jiroveci pneumopathy incidence in ANCA-associated vasculitis patients treated with Rituximab is found to be 1.2 %. Therefore, evidence and practice do not support the use of P. jiroveci pneumopathy chemoprophylaxis in all ANCA-associated vasculitis patients receiving Rituximab. CD4 cell count cut-off does not work well in patients treated with Rituximab as it does not reflect T cell impairment following B cell depletion. To help stratify the risk of both colonisation and P. jiroveci pneumopathy development, assessment of the patient's net state of immunodeficiency before administering Rituximab-including age, renal or lung involvement, previous infections due to T cell dysfunction, blood tests (lymphocytopenia, low CD4 cell count) and concomitant therapy-is warranted.
ACCESSION #
91279226

 

Related Articles

  • PCP prophylaxis with use of corticosteroids by neurologists. Kelly, Dearbhla M.; Cronin, Simon // Practical Neurology (BMJ Publishing Group);Apr2014, Vol. 14 Issue 2, p74 

    Pneumocystis jirovecii pneumonia (PCP) is increasingly reported in patients without HIV. Corticosteroids are a major risk factor, with up to 90% of patients receiving corticosteroid treatment prior to the development of PCP. In view of this, many specialties now prescribe PCP prophylaxis to...

  • Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis. Jiang, Xuqin; Mei, Xiaodong; Feng, Di; Wang, Xiaojing // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Pneumocystis jiroveci pneumonia (PCP) is frequently reported in lymphoma patients treated with rituximab-contained regimens. There is a trend toward a difference in PCP risk between bi- and tri-weekly regimens. The aims of this systemic review and meta-analysis were to estimate the risk for PCP...

  • Difficulties in diagnosing severe Pneumocystis jiroveci pneumonia after rituximab therapy for steroid-dependent nephrotic syndrome. Czarniak, Piotr; Załuska-Leśniewska, Iga; Zagożdżon, Ilona; Żurowska, Aleksandra // Pediatric Nephrology;Jun2013, Vol. 28 Issue 6, p987 

    A letter to the editor is presented which is concerned with the difficulties of diagnosing severe Pneumocystis jiroveci pneumonia after rituximab therapy for steroid-dependent nephrotic syndrome.

  • PNEUMOCYSTIS CARINII PNEUMONIA CHEMOPROPHYLAXIS IN HIV+ PATIENTS IN GLASGOW: AN AUDIT. Wardle, D.M.; Kennedy, D. // Sexually Transmitted Infections;Jun2003 Supplement 1, Vol. 79, pA22 

    Introduction: We audited chemoprophylactic use against Pneumocystis carinii pneumonia (PCP) in our HIV+ patients using US Public Health Service and Infectious Diseases Society of America USPHS/IDSA guidelines as a standard in the absence of definitive UK guidelines. Methods: Criteria for...

  • Immunosuppressants.  // Reactions Weekly;6/26/2010, Issue 1307, p28 

    The article describes seven cases of patients who experienced Pneumocystis carinii pneumonia (PCP) while receiving immunosuppression for a connective tissue disease or a bullous disorder, published in the June 2010 issue of the "Journal of the American Academy of Dermatology."

  • Immunosuppressants.  // Reactions Weekly;12/15/2012, Issue 1432, p28 

    The article describes the clinical cases of 14 patients who developed Pneumocystis pneumonia (PCP) secondary to immunosuppressants.

  • Immunosuppressants.  // Reactions Weekly;10/22/2011, Issue 1374, p20 

    The article describes the case of four patients who developed pneumocystis pneumonia (PCP) during treatment with immunosuppressants for immunobullous dermatoses.

  • Pneumocystis carinii pneumonia.  // MMWR: Morbidity & Mortality Weekly Report;6/27/1997 Supplement RR-12, Vol. 46, p4 

    Provides information on the disease pneumocystis carinii pneumonia. Recommendation made by authorities relating to the prevention of exposure to disease; Precautions that should be considered by adolescents, adults and pregnant women.

  • Prednisolone/rituximab.  // Reactions Weekly;11/2/2013, Issue 1476, p30 

    The article presents a case study of an infant who suffered from pneumocystis carinii pneumonia (PCP) while being treated with prednisolone and rituximab for autoimmune haemolytic anaemia (AIHA).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics